Kepler Cheuvreux Suisse SA Cuts Position in Stryker Corporation $SYK

Kepler Cheuvreux Suisse SA lowered its position in shares of Stryker Corporation (NYSE:SYK) by 54.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,453 shares of the medical technology company’s stock after selling 1,748 shares during the period. Kepler Cheuvreux Suisse SA’s holdings in Stryker were worth $477,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Norges Bank bought a new stake in Stryker in the 4th quarter worth approximately $1,822,272,000. Auto Owners Insurance Co lifted its holdings in shares of Stryker by 35,047.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after acquiring an additional 2,906,448 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares in the last quarter. Corient Private Wealth LLC grew its holdings in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Finally, Alliancebernstein L.P. raised its position in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In related news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. Company insiders own 4.60% of the company’s stock.

Stryker Price Performance

SYK stock opened at $326.41 on Monday. The firm’s 50-day moving average price is $309.80 and its two-hundred day moving average price is $338.75. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The stock has a market capitalization of $125.13 billion, a price-to-earnings ratio of 37.78, a PEG ratio of 2.09 and a beta of 0.77. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analyst Ratings Changes

Several research firms have issued reports on SYK. Citigroup cut their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 target price on shares of Stryker in a report on Friday, May 1st. UBS Group reduced their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. Finally, Wells Fargo & Company decreased their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.